Log in to search using one of your social media accounts:

 

BioNTech and Genentech partner to develop individualised mRNA cancer therapies

German biotechnology company BioNTech has agreed to collaborate with Roche ’s Genentech to develop and commercialise messenger ribonucleic acid (mRNA) based, individualised cancer vaccines.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: June 2018 Source:Molecular Immunology, Volume 98 Author(s): David Urbanavicius, Tara Alvarez, Georgina K. Such, Angus P.R. Johnston, Justine D. Mintern A complex and multifaceted relationship exists between cancer and the immune system. Advances in our understanding of this relationship have resulted in significant clinical attention in the possibilities of cancer immunotherapy. Harnessing the immune system’s potent and selective destructive capability is a major focus of attempts to treat cancer. Despite significant progress in the field, cancer therapy still remains significantly deficient, with ...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Spermidine‑induced growth inhibition and apoptosis via autophagic activation in cervical cancer. Oncol Rep. 2018 Apr 18;: Authors: Chen Y, Zhuang H, Chen X, Shi Z, Wang X Abstract Cervical cancer is the most common malignancy of the female reproductive tract, and the poor response to prophylactic vaccines and the toxicity of high‑dose chemotherapeutic drugs have limited their clinical application. Spermidine, a natural polyamine detected in all eukaryotic organisms, exhibits functions that promote longevity in multiple model systems and may constitute a promising agent for cancer treatment. However...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In the advent of Immune Checkpoint inhibitors (ICI) and of CAR-T adoptive T-cells, the new frontier in Oncology is Cancer Immunotherapy because of its ability to provide long term clinical benefit in metastati...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
li CA Abstract In recent years, cell-based therapies targeting the immune system have emerged as promising strategies for cancer treatment. This review summarizes manufacturing challenges related to production of antigen presenting cells as a patient-tailored cancer therapy. Understanding cell-material interactions is essential because in vitro cell culture manipulations to obtain mature antigen-producing cells can significantly alter their in vivo performance. Traditional antigen-producing cell culture protocols often rely on cell adhesion to surface-treated hydrophilic polystyrene flasks. More recent commercial ...
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: 9 April 2018 Source:Cancer Cell, Volume 33, Issue 4 Author(s): Stephen J. Russell, Glen N. Barber Selective destruction of neoplastic tissues by oncolytic viruses (OVs) leads to antigen-agnostic boosting of neoantigen-specific cytotoxic T lymphocyte (CTL) responses, making OVs ideal companions for checkpoint blockade therapy. Here we discuss the mechanisms whereby OVs modulate both adjuvanticity and antigenicity of tumor cells. Suppression of antitumor immunity after OV therapy has not been observed, possibly because viral antigen expression diminishes as the antiviral response matures, thereby progressi...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Georg Daeschlein, Claudia Sicher, Sebastian von Podewils, Rico Rutkowski, Michael Jünger Main topics in cancer treatment in dermatology are melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and metastatic skin tumors. Thereof stage IV MM because of fatal outcome is uf utmost importance. Despite some substantial therapeutic progress now in this entity by immunologic treatments alternatives are warranted when disease is progressing under therapy or the tumor basically appears refractory. National guid...
Source: Clinical Plasma Medicine - Category: Research Source Type: research
Intravesical instillation of Bacillus Calmette –Guérin (BCG) has been a first-line therapy for non-muscle invasive bladder cancer for the last four decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and in vivo in a preclinical model.
Source: Translational Research - Category: Research Authors: Source Type: research
Intravesical instillation of bacillus Calmette-Gu érin (BCG) has been a first-line therapy for non–muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live-attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and in vivo in a preclinical model.
Source: Translational Research - Category: Research Authors: Source Type: research
ute;n C, Aguilo N Abstract Intravesical instillation of bacillus Calmette-Guérin (BCG) has been a first-line therapy for non-muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live-attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and...
Source: Translational Research : the journal of laboratory and clinical medicine - Category: Laboratory Medicine Authors: Tags: Transl Res Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Pharmaceuticals | Vaccines